Bayer has agreed to acquire biopharmaceutical firm Perfuse Therapeutics for up to $2.45 billion. The deal secures full rights to PER-001, a Phase II clinical asset designed to treat Glaucoma and Diabetic Retinopathy by addressing underlying ischemia rather than traditional pressure-lowering methods.
Bayer has entered into a definitive agreement to fully acquire Perfuse Therapeutics, a clinical-stage biotechnology firm specializing in therapies for ischemia-induced ocular conditions. According to official disclosures, the transaction involves an initial payment of $300 million, with the total deal value potentially reaching $2.45 billion upon the achievement of specific development and regulatory milestones.
Bayer is a global enterprise with core competencies in life sciences, particularly pharmaceuticals, while Perfuse Therapeutics focuses on pioneering small molecule endothelin receptor antagonists. This acquisition is strategically significant as it shifts the therapeutic focus for Glaucoma and Diabetic Retinopathy (DR) away from intraocular pressure management toward neuroprotection and vascular improvement. The lead asset, PER-001, currently in Phase II trials, is being evaluated for its capacity to enhance visual fields and contrast sensitivity by reducing retinal ischemia.
With global Glaucoma cases projected to reach 112 million by 2040, the deal addresses a substantial unmet medical need for treatments that prevent irreversible vision loss independent of conventional surgical or pharmaceutical methods. For the ophthalmology sector and the broader biopharmaceutical industry, this move signals an intensifying race to secure next-generation treatments for age-related and diabetic vascular complications. The impact extends to healthcare providers and specialized clinics, which may soon have access to a new class of medication for the 146 million individuals globally affected by DR.
For investors, the high milestone-weighted valuation reflects Bayer's confidence in PER-001's ability to disrupt a saturated market and establish a first-in-class position in the multi-billion dollar ocular health segment. The effectiveness of the deal remains subject to customary antitrust clearances and shareholder approval.
About GlobeNewsInfo
GlobeNewsInfo.com is a business news platform providing latest updates on global business developments, projects, and contract opportunities across diverse sectors and regions. The platform is designed to serve as a trusted source of information for companies, investors, and professionals worldwide.